Marta Weinstock-Rosin
Directeur/Membre du Conseil chez Avraham Pharmaceuticals Ltd.
Profil
Marta Weinstock-Rosin is the founder of Spero Biopharma Ltd.
She is currently a Director at Avraham Pharmaceuticals Ltd.
and a Professor-Emeritus at The Hebrew University of Jerusalem.
Previously, she served as the President of The Israel Society for Neuroscience from 2005 to 2005.
Postes actifs de Marta Weinstock-Rosin
| Sociétés | Poste | Début |
|---|---|---|
Avraham Pharmaceuticals Ltd.
 Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Directeur/Membre du Conseil | - |
| The Hebrew University of Jerusalem | Corporate Officer/Principal | - |
Anciens postes connus de Marta Weinstock-Rosin
| Sociétés | Poste | Fin |
|---|---|---|
| The Israel Society for Neuroscience | President | 01/01/2005 |
Spero Biopharma Ltd.
 Spero Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Spero Biopharma Ltd. develops ladostigil an treatment for mild cognitive impairment. The company was founded by Marta Weinstock-Rosin and is headquartered in Tel Aviv-Yafo, Israel. | Fondateur | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
| The Israel Society for Neuroscience | |
Avraham Pharmaceuticals Ltd.
Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Health Technology |
Spero Biopharma Ltd.
Spero Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Spero Biopharma Ltd. develops ladostigil an treatment for mild cognitive impairment. The company was founded by Marta Weinstock-Rosin and is headquartered in Tel Aviv-Yafo, Israel. | Health Technology |
